pharma companies
Coverage of pharma companies in the Nexus archive.
- Fervor over top-selling drugs fuels biotech dealmaking
Biotech firms are attracting significant dealmaking and investor interest, with 37 biotech acquisitions over $1 billion this year driven by pharma companies seeking to strengthen pipelines before patent expirations. The Trump administration’s regulatory approach and profits from top-selling drugs are fueling mergers, while biotech IPOs are outperforming AI-related listings.
- Opinion: STAT+: Enough, already: the problem with clinical trial data collection
The clinical research industry collects excessive data in trials, with nearly 30% of data not directly informing key decisions. Since 2005, procedures, endpoints, and data points collected have increased significantly, leading critics to argue that the 'more is better' approach undermines trial effectiveness.
- STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices
European countries are taking divergent approaches to drug pricing, with the U.K. adopting industry-friendly policies under pressure from pharma companies and the Trump administration, while Germany proposes spending cuts and higher fees for the industry amid health budget deficits.